Allergy 4 All

Peanut Patch for Allergy Sufferers

A promising peanut allergy treatment tested by Seattle area doctors entered Phase III trials at the end of 2015.

 

In April 2015, the Viaskin Peanut patch made by French company DBV Technologies was awarded a breakthrough therapy designation by the U.S. Food and Drug Administration (FDA). The designation is intended to accelerate the development and review of treatments of serious conditions. It came after a Phase IIb multicenter clinical trial showed the patch increased the amount of peanut required to trigger an allergic reaction by at least tenfold.

 

The Viaskin Peanut patch administers peanut protein directly into the skin, where it activates an immune response without releasing antigens into the blood. Langerhan cells then transport the peanut protein into the lymph nodes where immune activity takes place. The intact proteins never enter the bloodstream, thereby reducing the chance of allergic reaction.

 

Dr. Stephen Tilles, a physician partner at Northwest Asthma & Allergy Center and executive director of the ASTHMA, Inc. Clinical Research Center, oversaw the study in nine Seattle-area participants. He works with the Seattle Food and Allergy Consortium (SeaFAC), which is dedicated to developing new allergy therapies.

 

Read the full Article here on Institute of Translational Health Sciences

Share

Contact us

You can contact us by phone or email

  • Phone: 086 0736297